India, Dec. 6 -- image credit- shutterstock

Mango Sciences, Inc., a US and India-based data and AI company, has announced a strategic partnership with ImmunoAdoptive Cell Therapy (ImmunoACT), Mumbai-based pioneering cell and gene therapy development company, to expand access and affordability of ImmunoACT's NexCAR19TMchimeric antigen receptor T-cell (CAR-T) for leukaemia and lymphoma.

The partnership enables patients to avail easy 0% interest EMI plans of up to 10 lakh to cover the cost of CAR-T. Additionally, a value-based offering of up to Rs 10 lakh can also be availed by clinically eligible patients.

NexCAR19TMis a first-of-its-kind product that has given patients in India access to this lifesaving, leading-edge therapy at an affor...